Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 278, Issue 6 47-6, 2000, Pages

  Kaul, Dhananjaya K ^a   Liu, Xiao Du ^a   Fabry, Mary E ^a   Nagel, Ronald L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Mean arterial pressure; Microcirculation; Sickle cell anemia; Vascular tone

Indexed keywords

ACETYLCHOLINE; AMINOGUANIDINE; ARGININE; HEMOGLOBIN S; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CREMASTER MUSCLE; ENDOTHELIUM INJURY; ERYTHROCYTE ADHESIVENESS; HEMODYNAMICS; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TRANSGENIC MOUSE; VASODILATATION;

EID: 0033921542     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2000.278.6.h1799     Document Type: Article

References (40)

1. Baez S. An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. Microvasc Res 5: 384-394, 1973.
2. Baker M and Wayland H. On-line volume flow rate and velocity profile measurement for blood in microvessels. Microvasc Res 7: 131-143, 1974.
3. Bank N, Aynedjian HS, Qiu J-H, Osei SY, Ahima RS, Fabry ME, and Nagel RL. Renal nitric oxide synthases in transgenic sickle mice. Kidney Int 50: 184-189, 1996.
4. Chen D and Kaul DK. Rheological and hemodynamic characteristics of red blood cells of mouse, rat and human. Biorheology 31: 103-113, 1994.
5. Conger J, Robinette J, Villar A, Raij L, and Shultz P. Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats. J Clin Invest 96: 631-638, 1995.
6. Corbett JA and McDaniel ML. Selective inhibition of inducible nitric oxide synthase by aminoguanidine. Methods Enzymol 268: 398-408, 1996.
7. De Jong PE, de Jong-van den Berb LTW, Donker AJM, and Statius van Eps LW. The influence of indomethacin on renal hemodynamics in sickle cell anemia. Clin Sci (Lond) 59: 245-250, 1980.
8. De Jong PE, Saleh AW, and de Zeeuw D. Urinary prostaglandin in sickle cell nephropathy: a defect in 9-ketoreductase activity? Clin Nephrol 22: 212-213, 1984.
9. S- and α-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci USA 89: 12155-12159, 1992.
10. Fabry ME, Sengupta A, Suzuka SM, Costantini F, Rubin EM, Hoftrichter J, Christoph G, Mancie E, Culberson D, Factor SM, and Nagel RL. A second generation of transgenic mouse model expressing HbS and HbS-Antilles results in increased phenotypic severity. Blood 86: 2419-2428, 1995.
11. Grell GAC, Alleyne GAO, and Serjeant GR. Blood pressure in adults with homozygous sickle cell disease (Letter). Lancet 2: 1166, 1981.
12. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfuction. J Clin Res 100: 2153-2157, 1997.
13. Hatch FE Jr, Crowe LR, Miles DE, Young JP, and Portner ME. Altered vascular reactivity in sickle hemoglobinopathy. Am J Hypertens 2: 2-8, 1989.
14. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 77: 214-237, 1991.
15. Johnson CS and Giorgio AJ. Arterial blood pressure in adults with sickle cell disease. Arch Intern Med 141: 891-893, 1981.
16. Kaul DK, Fabry ME, Costantini F, Rubin EM, and Nagel RL. In vivo demonstration of red cell-endothelial interactions, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 96: 2845-2853, 1995.
17. Kaul DK, Fabry ME, and Nagel RL. The pathophysiology of vascular obstruction in the sickle syndromes. Blood Rev 10: 29-44, 1996.
18. Kaul DK, Fabry ME, Windisch P, Baez S, and Nagel RL. Erythrocytes in sickle cell anemia are heterogeneous in their rheological and hemodynamic properties. J Clin Invest 72: 22-31, 1983.
19. Klug PP, Kaye N, and Jensen WN. Endothelial cell and vascular damage in the sickle cell disorders. Blood Cells 8: 175-184, 1982.
20. Knowles RG and Moncada S. Nitric oxide synthases in mammals. Biochem J 298: 249-258, 1994.
21. Kubes P, Suzuki M, and Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88: 4651-4655, 1991.
22. Lipowsky HH, Sheikh NU, and Katz DM. Intravital microscopy of capillary hemodynamics in sickle cell disease. J Clin Invest 80: 117-127, 1987.
23. Lonsdorfer J, Bogui P, Otayeck A, Bursaux E, Poyart C, and Cabannes R. Cardiorespiratory adjustments in chronic sickle cell anemia. Bull Eur Physiopath Respir 19: 339-344, 1983.
24. Mackie I, Bull H, and Brozovic M. Altered factor VIII complexes in sickle cell disease. Br J Hematol 46: 499-502, 1980.
25. Monsplaisir N, Merault G, Poyart C, Rhoda MD, Craescu C, Vidaud M, Galacteros F, Blouquit Y, and Rosa J. Hemoglobin S Antilles: a variant with a lower aolubility than hemoglobin S and producing sickle cell disease in heterozygotes. Proc Natl Acad Sci USA 83: 9363-9367, 1986.
26. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, and Yokoyama M. Hypotension and reduced nitric-oxide elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 102: 2061-2071, 1998.
27. Moncada S, Palmer RM, and Higgs FA. Nitric oxide physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109-142, 1991.
28. Rees DC, Cervi P, Grimwade D, O'Driscoll A, Hamilton M, Parker NE, and Porter JB. The metabolites of nitric oxide in sickle cell disease. Brit J Hematol 91: 834-837, 1995.
29. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Neinhuis AW, and Bonner RF. Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med 311: 1534-1538, 1984.
30. Rodgers GP, Walker EC, and Podgor MJ. Is "relative" hypertension a risk factor for vaso-occlusive complications in sickle cell disease? Am J Med Sci 305: 150-156, 1993.
31. Rubin EM, Witkowska HE, Spangler E, Curtin P Mohandas N, and Lubin BH. Hypoxia-induced in vivo sickling of transgenic mouse red cells. J Clin Invest 87: 639-647, 1991.
32. Seki J and Lipowsky HH. In vivo and in vitro measurements of red cell velocity under epifluorescent microscopy. Microvasc Res 38: 110-124, 1987.
33. Solovey A, Lin Y, Browne P, Choong S, Wayner E, and Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 337: 1584-1590, 1998.
34. Sowemimo-Coker SO, Haywood LJ, Meiselman HJ, and Francis RB Jr. Effects of normal and sickle erythrocytes on prostacyclin release by perfused human umblical cord vein. Am J Hematol 40: 276-282, 1992.
35. Sowemimo-Coker SO, Meiselman HJ, and Francis RB Jr. Increased circulating endothelial cells in sickle cell crisis. Am J Hematol 31: 263-265, 1989.
36. Tompkins W, Monti RR, and Intaglietta M. Velocity measurements by self-tracking correlator. Rev Sci Instrum 45: 647-649, 1974.
37. Wayland H and Johnson P. Erythrocyte velocity measurements in microvessels by a two-slit method. J Appl Physiol 22: 333-337, 1967.
38. Winer BJ. Statistical Principles in Experiment Design (2nd ed.). New York: McGraw Hill, 1971.
39. Xu X-P, Pollock JS, Tanner MA, and Myers PR. Hypoxia activates nitric oxide synthase and stimulates nitric oxide production in porcine coronary resistance arteriolar endothelial cells. Cardiovasc Res 30: 841-847, 1995.
40. Yamamoto H, Bossaller C, Cartwright J Jr, and Henry PD. Videomicroscopic demonstration of defective cholinergic arteriolar vasodilation in atherosclerotic rabbit. J Clin Invest 81: 1752-1758, 1988.